Genentech, Inc.

Gilead Biologics, Inc.

Genetech, Inc.

Gilead Sciences, Inc.

Ashibio, Inc.

Victoria Smith

William I Wood

Austin L Gurney

Audrey Goddard

Paul J Godowski

Colin K Watanabe

Kevin P Baker

Zemin Zhang

Luc Roland Desnoyers

Dan L Eaton

J Christopher Grimaldi

Daniel Tumas

Ellen Filvaroff

Timothy Andrew Stewart

James Pan

Wei-Qiang Gao

Sherman Fong

Mary E Gerritsen

Kenneth J Hillan

P Mickey Williams

Steven W Sherwood

Scott Alan McCauley

Maureen H Beresini

Laura Deforge

Jian Chen

Gretchen Frantz

Paul Polakis

Jo-Anne Hongo

Thomas J Wu

Jean Philippe Stephan

Napoleone Ferrara

David Botstein

Margaret Ann Roy

Frederic J De Sauvage

Nicholas F Paoni

Hartmut Koeppen

Alison Kay Holzer

Susan D Spencer

Hector Rodriguez

Carlos Aurelio Garcia

Allen J Ebens

Peter Van Vlasselaer

Derek Marshall

Scott Ogg

Vivian E Barry

Donna Hiroko Tokuoka Biermann

Miho Oyasu

Andrew G Polson

Diane Pennica

Jean-Philippe F Stephan

Heidi S Phillips

Ruihuan Chen

Belinda Cairns

Wesley Chang

Patrick Dowd

Harmut Koeppen

Susan D Spenser

Frederic J Desauvage

Thomas D Wu

Richard L Vandlen

Anan Chuntharapai

Dorothy French

Meredith C Hazen

Chie Sakanaka

Craig W Crowley

Michael J Hawkins

Fred De Sauvage

Susanna Y Stinson

Kerstin N Schmidt

Jing Li

Pankaj Bhargava

Suzie J Scales

Chae Janeka Reed

Joanne I Adamkewicz

Zung Thai

Andrew Poison

Maria Teresa Pisabaro

Scott Mccauley

Scott Alan Mccauley

Jr Allen Ebens

Allen Jr Ebens

Jo-Anne S Hongo

Donna Hiroko Biermann

The present disclosure provides methods and compositions for treating non hereditary heterotopic ossification and genetic heterotopic ossification, such as fibrodysplasia ossificans progressive (FOP). Such methods are directed to MMP-9 inhibition in therapeutic applications.

Methods for treating fibrodysplasia ossificans progressiva

The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an Ig light chain (or functional fragment thereof).

Antibodies to matrix metalloproteinase 9

The present disclosure provides compositions and methods of use involving binding proteins, e.g., antibodies and antigen-binding fragments thereof, that bind to the matrix metalloproteinase-9 (MMP9) protein (MMP9 is also known as gelatinase-B), such as where the binding proteins comprise an immunoglobulin (Ig) heavy chain (or functional fragment thereof) and an l=g light chain (or functional fragment thereof).

The present application relates to anti-LOX and anti-LOXL2 antibodies and their use in purification, diagnostic and therapeutic methods. Antibodies include monoclonal antibodies, humanized antibodies and functional fragments thereof. Anti-LOX and anti-LOXL2 antibodies can be used to identify and treat conditions such as a fibrotic condition, angiogenesis, or to prevent a transition from an epithelial cell state to a mesenchymal cell state.

LOX and LOXL2 inhibitors and uses thereof

Methods of treating rheumatoid arthritis using antibodies to matrix metalloproteinase 9

Method of detecting human matrix metalloproteinase 9 using antibodies

Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix.

Chemotherapeutic methods and compositions

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

Compositions and methods for the treatment of tumor of hematopoietic origin

Disclosed herein are amino acid sequences, and encoding nucleotide sequences, of isolated catalytic domains of the LOX and LOXL2 proteins from human and mouse. Methods for the preparation and use of these isolated catalytic domains are also provided.

Catalytic domains from lysyl oxidase and LOXL2

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereof

NLRR-1 antagonists and methods of their use in treating cancer and other disorders are provided.

NLRR-1 antagonists and uses thereof

The present disclosure provides lysyl oxidase-like-2 (LOXL2) polypeptide binding agents, including, for example, antibodies that specifically bind a LOXL2 polypeptide; and further provides compositions comprising same. The binding agents can be used in various treatment and diagnostic methods, which are also provided.

Antibodies that bind to lysyl oxidase-like 2 (LOXL2)

The present disclosure provides methodology and compositions for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysyl oxidase-like proteins, an inhibitor of LOX or LOXL, or a synergistic combination thereof combined with other therapeutic agents. Methods and compositions for diagnosing or monitoring various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, are also provided. Also provided herein are methods and related compositions, medical devices, systems and kits for preventing or treating various diseases and conditions associated with fibrosis with compositions comprising inhibitors of LOX or LOXL.

Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis

Growing community of inventors

Burlingame, CA, United States of America

Victoria Smith